Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s share price was up 3.7% during trading on Monday . The stock traded as high as $0.3573 and last traded at $0.3573. Approximately 5,000 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 7,928 shares. The stock had previously closed at $0.3444.
Defence Therapeutics Stock Performance
The company has a fifty day moving average price of $0.32 and a two-hundred day moving average price of $0.38.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Recommended Stories
- Five stocks we like better than Defence Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
